Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest From WuXi Biologics

New Singapore Center For WuXi As It Looks Beyond China

The Southeast Asian island nation could emerge a winner as China and Hong Kong continue to show few signs of easing their strict COVID policies and companies look to diversify their global supply chains.

Manufacturing Supply Chain

Coronavirus Update: Vir, WuXi Terminate COVID-19 Antibody Pact

Xevudy, which was part of the deal, has already seen restrictions on its use due to diminished efficacy against Omicron. Plus, Ocugen is back in the game as the FDA has released the clinical hold on its Phase II/III vaccine trial, while Pfizer/BioNTech release new booster shot data for Comirnaty in children aged 6 months-5 years.

Coronavirus COVID-19 Vaccines

The Quality Lowdown: Stability Testing, OOS Findings, Major Quality Failures Cited

Cadila (now Zydus), Wuxi, Accu-Biochem, Agropharma, Dr Retter stung by US FDA inspections that focused on failings in a range of core quality areas.

Manufacturing Quality

US Puts China's WuXi Biologics On New Export Restriction List

The latest move signals a toughening stance in China over sensitive technology exports, as the bilateral relationship with the US continues its free fall.

China Trade Policy
See All

Company Information

  • Industry
  • Contract Research Organization-CRO
  • Pharmaceuticals
  • Services
  • Biotechnology
    • Large Molecule